KR101975299B1 - 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도 - Google Patents

인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도 Download PDF

Info

Publication number
KR101975299B1
KR101975299B1 KR1020177021530A KR20177021530A KR101975299B1 KR 101975299 B1 KR101975299 B1 KR 101975299B1 KR 1020177021530 A KR1020177021530 A KR 1020177021530A KR 20177021530 A KR20177021530 A KR 20177021530A KR 101975299 B1 KR101975299 B1 KR 101975299B1
Authority
KR
South Korea
Prior art keywords
compound
tamoxifen
formula
tumor
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177021530A
Other languages
English (en)
Korean (ko)
Other versions
KR20170129688A (ko
Inventor
루이치웅 란
Original Assignee
베이징 안 젠 시 바이오-메디컬 테크놀로지 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 안 젠 시 바이오-메디컬 테크놀로지 컴퍼니 리미티드 filed Critical 베이징 안 젠 시 바이오-메디컬 테크놀로지 컴퍼니 리미티드
Publication of KR20170129688A publication Critical patent/KR20170129688A/ko
Application granted granted Critical
Publication of KR101975299B1 publication Critical patent/KR101975299B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177021530A 2015-01-27 2016-01-25 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도 Active KR101975299B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510040470.5 2015-01-27
CN201510040470.5A CN104592091B (zh) 2015-01-27 2015-01-27 一种含吲哚乙酸核心结构的化合物及其应用
PCT/CN2016/071934 WO2016119643A1 (zh) 2015-01-27 2016-01-25 一种含吲哚乙酸核心结构的化合物及其应用

Publications (2)

Publication Number Publication Date
KR20170129688A KR20170129688A (ko) 2017-11-27
KR101975299B1 true KR101975299B1 (ko) 2019-05-07

Family

ID=53118197

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177021530A Active KR101975299B1 (ko) 2015-01-27 2016-01-25 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도

Country Status (7)

Country Link
US (1) US10494341B2 (enExample)
EP (2) EP3978473A1 (enExample)
JP (1) JP6442615B2 (enExample)
KR (1) KR101975299B1 (enExample)
CN (1) CN104592091B (enExample)
AU (1) AU2016212552B2 (enExample)
WO (1) WO2016119643A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592091B (zh) 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用
CN109180521B (zh) * 2018-09-05 2021-08-31 中国人民解放军陆军军医大学 一种抗肿瘤化合物及其制备方法、用途
US12186332B2 (en) * 2019-06-27 2025-01-07 Stowers Institute For Medical Research Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
EP4417599A4 (en) * 2021-10-15 2025-11-19 Beijing Anjianxi Bio Medical Tech Co Ltd ALKYL ALCOHOL DERIVATIVE 2,3-DIMETHOXY-5-METHYL-1,4-BENZOQUINONE AND ITS USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654349A (en) * 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
CN1237162A (zh) * 1996-11-12 1999-12-01 美国家用产品公司 Cox－2的茚抑制剂
WO2014138922A1 (en) * 2013-03-15 2014-09-18 Indanio Bioscience Inc. Uses for idebenone and related benzoouinones in ppar-related diseases and conditions
CN104592091B (zh) * 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use

Also Published As

Publication number Publication date
JP2018505184A (ja) 2018-02-22
US10494341B2 (en) 2019-12-03
CN104592091A (zh) 2015-05-06
EP3252039A4 (en) 2018-07-25
KR20170129688A (ko) 2017-11-27
WO2016119643A1 (zh) 2016-08-04
EP3252039A1 (en) 2017-12-06
AU2016212552B2 (en) 2018-10-25
AU2016212552A1 (en) 2017-08-17
CN104592091B (zh) 2017-07-04
EP3252039B1 (en) 2021-11-03
JP6442615B2 (ja) 2018-12-19
EP3978473A1 (en) 2022-04-06
US20180022700A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
KR101975299B1 (ko) 인돌아세트산의 코어구조를 함유하는 화합물 및 그의 용도
Alidmat et al. Synthesis, characterization, molecular docking and cytotoxicity evaluation of new thienyl chalcone derivatives against breast cancer cells
Ma et al. Synthesis and antitumor activity of novel indole derivatives containing α-aminophosphonate moieties
JP6827942B2 (ja) トリプトリドのｃ１４ヒドロキシルエステル化アミノ酸誘導体、ならびにその製造方法および使用
CN110156822B (zh) 一种萘酚-苯硼酸类化合物及其制备方法和用途
CN114195814B (zh) 羟基萘酮-苯硼酸类化合物、制备方法和用途
EP3922628B1 (fr) Composés cytotoxiques inhibiteurs de la polymérisation de la tubuline
WO2010059142A1 (en) Anthraquinone dioximes and uses thereof
EP4273150A1 (en) Tricyclic compound, and preparation method therefor and medical use thereof
JP2021512951A (ja) ゲムシタビン誘導体の新規小分子薬物コンジュゲート
US11117907B2 (en) Curcuminoid-inspired synthetic compounds as anti-tumor agents
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
AU2011274194B2 (en) Phenyl nitrone compounds containing stilbene segment and use thereof
HK40070404A (en) Compound containing an indoleacetic acid core structure and use thereof
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
HK1241872A1 (en) Compound containing indoleacetic acid core structure and use thereof
CA2888379A1 (fr) Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer
WO2011147254A1 (zh) 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用
EP3049386B1 (en) Compounds useful in the treatment of neoplastic diseases
KR101495834B1 (ko) 신규한 1,2-디페닐에탄 유도체 및 이의 안드로겐 수용체 조절 효과
HK1241872B (en) Compound containing indoleacetic acid core structure and use thereof
CA3209238A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
WO2025029660A1 (en) Compounds with selectivity for certain cancers
CA3140417A1 (en) Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof
CN111285900A (zh) 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20170731

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190416

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190429

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220422

Start annual number: 4

End annual number: 4